Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Growth”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT00683358
What this trial is testing

Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Who this might be right for
Pancreatic CancerPancreas Neoplasms
Tokyo University 14
Not applicableWithdrawnNCT06075615
What this trial is testing

Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer
Not applicableEnded earlyNCT02213536
What this trial is testing

Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.

Who this might be right for
Metastatic Brain Cancer
HCA International Limited 5
Not applicableStudy completedNCT01393821
What this trial is testing

Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Who this might be right for
Dermatologic ComplicationsMalignant NeoplasmPain
Mayo Clinic 27
Testing effectiveness (Phase 2)Study completedNCT00889382
What this trial is testing

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Who this might be right for
Ovarian CancerSolid Tumors
Astellas Pharma Inc 152
Not applicableStudy completedNCT05412459
What this trial is testing

99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

Who this might be right for
HER2-positive Breast CancerFemale
Tomsk National Research Medical Center of the Russian Academy of Sciences 15
Large-scale testing (Phase 3)Looking for participantsNCT07710885
What this trial is testing

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Taiho Pharmaceutical Co., Ltd. 784
Testing effectiveness (Phase 2)Study completedNCT00879359
What this trial is testing

Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

Who this might be right for
Endometrial Carcinoma
The Cleveland Clinic 15
Early research (Phase 1)Study completedNCT00768391
What this trial is testing

Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

Who this might be right for
Solid Tumors
Eli Lilly and Company 20
Testing effectiveness (Phase 2)Study completedNCT00444535
What this trial is testing

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 52
Not applicableStudy completedNCT03309462
What this trial is testing

Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy

Who this might be right for
Lung Cancer
Shanghai Chest Hospital 50
Testing effectiveness (Phase 2)Study completedNCT03878823
What this trial is testing

Safety and Pharmacokinetics of ODM-209

Who this might be right for
Prostate Cancer MetastaticAdvanced Breast CancerCastration-resistant Prostate Cancer+1 more
Orion Corporation, Orion Pharma 38
Not applicableStudy completedNCT04370860
What this trial is testing

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Who this might be right for
EGFR Exon 19 MutationTumor Progression
National Taiwan University Hospital 1,000
Early research (Phase 1)WithdrawnNCT00945360
What this trial is testing

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

Who this might be right for
Symptomatic or Large Uterine Fibroids
American University of Beirut Medical Center
Not applicableStudy completedNCT01255150
What this trial is testing

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Study completedNCT01136733
What this trial is testing

E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Who this might be right for
Metastatic Renal Cell Carcinoma
Eisai Inc. 173
Not applicableStudy completedNCT05584644
What this trial is testing

Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Neoplasms+2 more
Pfizer 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699952
What this trial is testing

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationHER2
Yongsheng Wang 35
Not applicableStudy completedNCT02580799
What this trial is testing

Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Who this might be right for
Breast Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05323955
What this trial is testing

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Who this might be right for
Brain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast Cancer
Carey Anders, M.D. 48
Next Page